Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients With Active Systemic Lupus Erythematosus.

NCT00383214 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00383214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00383214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients With Active Systemic Lupus Erythematosus.
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2005
Completion date
March 31, 2007
Enrollment
54 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus